Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.58 |
| ▸ | NT5E | P21589 | 2/20 | 0.52 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034220 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL32679036 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL26906442 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL32679034 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL8359092 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL25874925 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL21245356 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL21284194 | 1.00 | TYMP (0.58) | TYMPNT5EP2RY12ADORA1ADORA2A | |
| SCHEMBL18797935 | 0.94 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL18797864 | 0.94 | TYMP (0.58) | TYMPP2RY12ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11466047-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2022-10-11 | — | — | US | disclosed |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3752516-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | MERCK SHARP & DOHME CORP. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3891165-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891166-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | Aduro Biotech, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2019160884-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-15 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2018208667-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2018-03-08 | — | — | US | disclosed |
| EP-3268035-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" -DEPENDENT SIGNALLING | Aduro BioTech, Inc. (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016145102-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" -DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-1999029702-A2 | METHOD FOR SYNTHESIZING 9-(2,3-DIDEOXY-2-FLUORO-β-D-THREO-PENTOFURANOSYL)ADENINE (β-FddA) | THE GOVERNMENT OF THE UNITED STATES OF AMERICA REPPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033431-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | TYMP 1904/4885NT5E 1244/4885P2RY12 320/4885 |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | TYMP 6/4885NT5E 102/4885P2RY12 1690/4885 |
| US-20220024964-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | TYMP 2010/4885NT5E 1251/4885P2RY12 324/4885 |
| US-11466047-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | TYMP 2012/4885NT5E 1360/4885P2RY12 360/4885 |
| US-20220033435-A1 | Cyclic Di-Nucleotide Compounds as STING Agonists | STING1, CGAS, IFNAR1 | TYMP 2032/4885NT5E 1230/4885P2RY12 326/4885 |
| US-11339185-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | TYMP 6/4885NT5E 102/4885P2RY12 1690/4885 |
| US-20190248828-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | TYMP 6/4885NT5E 102/4885P2RY12 1690/4885 |
| US-10449211-B2 | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling | STING1, IRF3, CGAS | TYMP 1876/4885NT5E 133/4885P2RY12 73/4885 |
| US-20180064745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | TYMP 1369/4885NT5E 115/4885P2RY12 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.